Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
When adalimumab is used in children, especially in the first 3 months of treatment, in addition to the AEs recorded in the drug package insert, close attention should be paid to the new potential AEs off-label to ensure the safety of adalimumab in children.
Authors
- Yamin Shu (ORCID: https://orcid.org/0000-0002-1532-8135)
- Wenting Zhang (ORCID: https://orcid.org/0000-0003-4166-9352)
- Qilin Zhang (ORCID: https://orcid.org/0000-0002-4779-3875)
- Sainan Shu
- Ziqi Xu (ORCID: https://orcid.org/0009-0008-7117-2762)
Institutions
- Tongji Hospital (CN)
- Chinese People's Liberation Army (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-08-05
- DOI
- https://doi.org/10.3390/ph17081028
- Citations
- 6
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 6.66
Funders
- National Natural Science Foundation of China